The EU Court of Justice renders a preliminary ruling stating that a dispute between an originator and a generics manufacturer constitutes evidence that they are potential competitors (Generics - UK / GlaxoSmithKline / Actavis / Xellia Pharmaceuticals / Merck / Alpharma)

On 30 January 2020, the Court of Justice of the EU rendered its preliminary ruling in Case C-307/18 ā€“ Generics (UK) and Others v CMA (Paroxetine). The case originated in a preliminary reference made by the UK Competition Appeal Tribunal (CAT) relating to an

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Stamatis Drakakakis, Argyrios Papaefthymiou, Ellie Gavriilidou, The EU Court of Justice renders a preliminary ruling stating that a dispute between an originator and a generics manufacturer constitutes evidence that they are potential competitors (Generics - UK / GlaxoSmithKline / Actavis / Xellia Pharmaceuticals / Merck / Alpharma), 30 January 2020, e-Competitions Intellectual property, Art. N° 100061

Visites 43

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues